KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Current Deferred Revenue (2019 - 2023)

GoodRx Holdings (GDRX) has disclosed Current Deferred Revenue for 5 consecutive years, with $10.8 million as the latest value for Q1 2023.

  • Quarterly Current Deferred Revenue rose 4.3% to $10.8 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $10.8 million through Mar 2023, up 4.3% year-over-year, with the annual reading at $7.9 million for FY2022, 15.01% up from the prior year.
  • Current Deferred Revenue hit $10.8 million in Q1 2023 for GoodRx Holdings, up from $7.9 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $11.5 million in Q2 2022 to a low of $3.5 million in Q4 2019.
  • Historically, Current Deferred Revenue has averaged $8.5 million across 5 years, with a median of $8.5 million in 2021.
  • Biggest five-year swings in Current Deferred Revenue: soared 98.44% in 2020 and later increased 0.25% in 2021.
  • Year by year, Current Deferred Revenue stood at $3.5 million in 2019, then skyrocketed by 98.44% to $6.9 million in 2020, then rose by 0.25% to $6.9 million in 2021, then rose by 15.01% to $7.9 million in 2022, then skyrocketed by 36.24% to $10.8 million in 2023.
  • Business Quant data shows Current Deferred Revenue for GDRX at $10.8 million in Q1 2023, $7.9 million in Q4 2022, and $11.0 million in Q3 2022.